Barclays
ZYNE

Barclays’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

Barclays’s Portfolio ZYNE Stock Details ZYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-100
Closed -$1K – 6952
2019
Q3 		$1K Sell
100
-300
-75% -$3.38K ﹤0.01% 6627
2019
Q2 		$5K Sell
400
-5,000
-93% -$57.7K ﹤0.01% 6702
2019
Q1 		$29K Buy
5,400
+3,400
+170% +$16.5K ﹤0.01% 6200
2018
Q4 		$6K Buy
2,000
+1,800
+900% +$9.86K ﹤0.01% 6411
2018
Q3 		$2K Buy
+200
New +$1.53K ﹤0.01% 6973
2018
Q2 		– Sell
-500
Closed -$4K – 7386
2018
Q1 		$4K Sell
500
-300
-38% -$3.23K ﹤0.01% 6830
2017
Q4 		$10K Buy
+800
New +$9.17K ﹤0.01% 6520

Other funds holding ZYNE

EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

Barclays's ZYNE Position: Q4 2021 in Review

Barclays sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q4 2021, closing a stake of 7,268 shares — an estimated $31K sold.

Barclays first reported a position in ZYNE in Q2 2016 and held it in 20 quarters. The position peaked at $870K in Q2 2019. 62 funds tracked by Wall St. Rank hold ZYNE as of Q4 2021.

  • Barclays reported no remaining Zynerba Pharmaceuticals, Inc position as of Q4 2021 after selling out during the quarter.
  • Barclays sold 7,268 Zynerba Pharmaceuticals, Inc shares in Q4 2021, an estimated $31K.
  • Barclays first reported a position in Zynerba Pharmaceuticals, Inc in Q2 2016 and held it in 20 quarters.
  • Barclays's Zynerba Pharmaceuticals, Inc position peaked at $870K in Q2 2019.
  • 62 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q4 2021.

Based on Barclays's 13F filing for Q4 2021, filed 14 Feb 2022.